 | Up a level |
Mushtaq, Rao; Cortot, Alexis B; Gautschi, Oliver; Mazieres, Julien; Camidge, D Ross (2022). PD-1/PD-L1 inhibitor activity in patients with gene-rearrangement positive non-small cell lung cancer-an IMMUNOTARGET case series. Translational lung cancer research, 11(12), pp. 2412-2417. AME Publishing 10.21037/tlcr-22-329
Panje, Cédric; Lupatsch, J; Barbier, M; Pardo, E; Lorez, M; Dedes, K J; Aebersold, D. M.; Plasswilm, Ludwig; Gautschi, O.; Schwenkglenks, M. (2020). A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland. Annals of oncology, 31(4), pp. 501-506. Oxford University Press 10.1016/j.annonc.2020.01.007
Delaunay, Myriam; Cadranel, Jacques; Lusque, Amélie; Meyer, Nicolas; Gounant, Valérie; Moro-Sibilot, Denis; Michot, Jean-Marie; Raimbourg, Judith; Girard, Nicolas; Guisier, Florian; Planchard, David; Metivier, Anne-Cécile; Tomasini, Pascale; Dansin, Eric; Pérol, Maurice; Campana, Marion; Gautschi, Oliver; Früh, Martin; Fumet, Jean-David; Audigier-Valette, Clarisse; ... (2017). Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. European respiratory journal, 50(2) European Respiratory Society 10.1183/13993003.00050-2017
Rothschild, Sacha; Gautschi, Oliver; Batliner, Jasmin; Gugger, Mathias; Fey, Martin; Tschan, Mario (2017). MicroRNA-106a targets autophagy and enhances sensitivity of lung cancer cells to Src inhibitors. Lung cancer, 107, pp. 73-83. Elsevier 10.1016/j.lungcan.2016.06.004
Stutz, Emanuel; Gautschi, Oliver; Fey, Martin F.; Gugger, Mathias; Tschan, Mario; Rothschild, Sacha I. (2014). Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology. Future oncology, 10(2), pp. 211-217. Future Medicine Ltd. 10.2217/fon.13.179
Frauenfelder, T; Puhan, M A; Lazor, R; Von Garnier, Christophe; Bremerich, J; Niemann, T; Christe, Andreas; Montet, X; Gautschi, Oliver; Weder, Bruno J.; Kohler, Martin (2014). Early detection of lung cancer: a statement from an expert panel of the Swiss university hospitals on lung cancer screening. Respiration, 87(3), pp. 254-264. Karger 10.1159/000357049
Burmeister, H; Aebi, S; Studer, C; Fey, M.F.; Gautschi, O (2012). Adherence to ESMO clinial recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. Supportive care in cancer, 20(1), pp. 141-7. Berlin: Springer 10.1007/s00520-010-1079-3
Rothschild, Sacha I; Kappeler, Andreas; Ratschiller, Daniel; Betticher, Daniel C; Tschan, Mario P; Gugger, Mathias; Gautschi, Oliver (2011). The stem cell gene "inhibitor of differentiation 1" (ID1) is frequently expressed in non-small cell lung cancer. Lung cancer, 71(3), pp. 306-11. Amsterdam: Elsevier 10.1016/j.lungcan.2010.06.018
Ghadjar, Pirus; Burkhard, Fiona C; Gautschi, Oliver; Thalmann, George N; Studer, Urs E (2011). Induction chemotherapy for unresectable urothelial carcinoma of the bladder. BJU international, 107(6), pp. 894-7. Oxford: Blackwell Science 10.1111/j.1464-410X.2010.09574.x
Ruhstaller, Thomas; Pless, Miklos; Dietrich, Daniel; Kranzbuehler, Helmut; von Moos, Roger; Moosmann, Peter; Montemurro, Michael; Schneider, Paul M; Rauch, Daniel; Gautschi, Oliver; Mingrone, Walter; Widmer, Lucas; Inauen, Roman; Brauchli, Peter; Hess, Viviane (2011). Cetuximab in combination with chemoradiotherapy before surgery in patients with resectable, locally advanced esophageal carcinoma: a prospective, multicenter phase IB/II Trial (SAKK 75/06). Journal of clinical oncology, 29(6), pp. 626-31. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2010.31.9715
Rothschild, Sacha I; Gautschi, Oliver; Haura, Eric B; Johnson, Faye M (2010). Src inhibitors in lung cancer: current status and future directions. Clinical lung cancer, 11(4), pp. 238-42. New York, N.Y.: Elsevier 10.3816/CLC.2010.n.030
Gautschi, Oliver (2010). The polyamine metabolism: renaissance of an old pathway in oncology. Clinical lung cancer, 11(2), pp. 80-1. New York, N.Y.: Elsevier 10.3816/CLC.2010.n.010
Gautschi, O; Mack, PC; Gandara, DR; Rosell, R. (2010). Pharmacogenomics in Lung Cancer: Predictive Biomarkers for Chemotherapy. In: Pass, HL; Carbone, DP; Johnson, DH; Minna, JD; Turrisi, AT; Scagliotti, GV (eds.) Lung Cancer, Prinicples and Practice. Baltimore USA: Lippincott Williams & Wilkins
Rothschild, S; Gautschi, O (2010). KRAS bei anderen Tumoren. In: Bremen et al.: UNI-MED
Gautschi, Ol; Pless, M (2010). Swiss Trials in Thoracic Oncology. In: Magazine of European Medical Oncology.
Rothschild, S; Betticher, D; Ochsenbein, A; Stahel, R; Bubendorf L.Gugger, M.; Brutsche, M; Pless, M; Gautschi, O (2010). Bedeutung der Histologie für die Therapie des fortgeschrittenen, nicht-kleinzelligen Bronchuskarzinoms. In: Swiss Med Forum
Rothschild, S; Gautschi, O (2010). NSCLC bei Patienten in reduziertem Allgemeinzustand: Mehr oder weniger Chemotherapie? In: Leading Opinions Hämatologie & Onkologie
Rothschild, S; Gautschi, O (2010). Die molekulare Behandlung des Kolonkarzinoms. In: Schweizer Zeitschrift für Onkologie
Purnell, Phillip R; Mack, Philip C; Tepper, Clifford G; Evans, Christopher P; Green, Tim P; Gumerlock, Paul H; Lara, Primo N; Gandara, David R; Kung, Hsing-Jien; Gautschi, Oliver (2009). The Src inhibitor AZD0530 blocks invasion and may act as a radiosensitizer in lung cancer cells. Journal of thoracic oncology, 4(4), pp. 448-54. Hagerstown, Md.: Wolters Kluwer Health/Lippincott Williams & Wilkins 10.1097/JTO.0b013e31819c78fb
Gandara, DR; Kawaguchi, T; Crowley, J; Moon, J; Furuse, K; Kawahara, M; Teramukai, S; Ohe, Y; Kubota, K; Williamson, SK; Gautschi, O; Lenz, HJ; McLeod, HL; Lara, PN Jr; Coltman, CA Jr; Fukuoka, M; Saijo, N; Fukushima, M; Mack, PC (2009). Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. Journal of clinical oncology, 27(21), pp. 3540-3546. Alexandria, Va.: American Society of Clinical Oncology 10.1200/JCO.2008.20.8793
Ho, Cheryl; Ochsenbein, Adrian F; Gautschi, Oliver; Davies, Angela M (2008). Early clinical trial experience with vaccine therapies in non-small-cell lung cancer. Clinical lung cancer, 9 Suppl 1, S20-S27. New York, N.Y.: Elsevier 10.3816/CLC.2008.s.004
Gautschi, Oliver; Heighway, Jim; Mack, Philip C; Purnell, Phillip R; Lara, Primo N; Gandara, David R (2008). Aurora kinases as anticancer drug targets. Clinical cancer research, 14(6), pp. 1639-48. Philadelphia, Pa.: American Association for Cancer Research 10.1158/1078-0432.CCR-07-2179
Gautschi, Oliver; Tepper, Clifford G; Purnell, Phillip R; Izumiya, Yoshihiro; Evans, Christopher P; Green, Tim P; Desprez, Pierre Y; Lara, Primo N; Gandara, David R; Mack, Philip C; Kung, Hsing-Jien (2008). Regulation of Id1 expression by SRC: implications for targeting of the bone morphogenetic protein pathway in cancer. Cancer research, 68(7), pp. 2250-8. Birmingham, Ala.: American Association for Cancer Research AACR 10.1158/0008-5472.CAN-07-6403
Gautschi, O (2008). Pharmacogenomic Approaches to Individualizing Chemotherapy for Non-.Small Cell Lung Cancer. Clinical lung cancer, 2008;9(S3), pp. 129-38. New York, N.Y.: Elsevier 10.3816/CLC.2008.s.019
Gautschi, Oliver; Ratschiller, Daniel; Gugger, Mathias; Betticher, Daniel C; Heighway, Jim (2007). Cyclin D1 in non-small cell lung cancer: a key driver of malignant transformation. Lung cancer, 55(1), pp. 1-14. Amsterdam: Elsevier 10.1016/j.lungcan.2006.09.024
Ziegler, Annemarie; Seemayer, Christian A; Hinterberger, Marc; Vogt, Peter; Bigosch, Colette; Gautschi, Oliver; Tornillo, Luigi; Betticher, Daniel C; Moch, Holger; Stahel, Rolf A (2007). Low prevalence of SV40 in Swiss mesothelioma patients after elimination of false-positive PCR results. Lung cancer, 57(3), pp. 282-91. Amsterdam: Elsevier 10.1016/j.lungcan.2007.03.025
Gautschi, O; Huegli, B; Ziegler, A; Gugger, M; Heighway, J; Ratschiller, D; Mack, P C; Gumerlock, P H; Kung, H J; Stahel, R A; Gandara, D R; Betticher, D C (2007). Origin and prognostic value of circulating KRAS mutations in lung cancer patients. Cancer letters, 254(2), pp. 265-73. Amsterdam: Elsevier 10.1016/j.canlet.2007.03.008
Gandara, David R; Davies, Angela M; Gautschi, Oliver; Mack, Philip C; Lau, Derick H; Lara, Primo N; Hirsch, Fred R (2007). Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. Clinical lung cancer, 8 Suppl 2, S61-S67. New York, N.Y.: Elsevier 10.3816/CLC.2007.s.003
Ho, C; Davies, AM; Lara, PN; Gautschi, O; Mack, PC; Gumerlock, PH; Gandara, DR (2007). Molecular Targeting in Oncology. In: (pp. 20-40). New York: Humana Press
Gautschi, O (2007). Cellular and molecular biology of lung cancer as the basis for targeted therapy. In: (pp. 30-40). Informa Healthcare
Ho, C; Gautschi, O; Lara, PN; Gandara, DR; Davies, AM (2007). Lung cancer vaccines. In: (pp. 50-60). Informa Healthcare
Gautschi, Oliver; Zangemeister-Wittke, U.; Stahel, R. A. (2003). Comment on “A pilot trial of G3139, a bcl-2 antisense oligonucleotide, and paclitaxel in patients with chemorefractory small-cell lung cancer”, by C. M. Rudin et al. (Ann Oncol 2002; 13: 539–545). Annals of oncology, 14(1), p. 170. Oxford University Press 10.1093/annonc/mdg001
